KRBPQ.US Kiromic BioPharma, Inc.

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 15, 2026
Market cap
USD 265.00
P/E
-
P/B
11.55x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2024.

Is KRBPQ.US undervalued?

Graham number

The Graham number of Kiromic BioPharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kiromic BioPharma, Inc. fundamental analysis

No fundamental analysis for Kiromic BioPharma, Inc. yet.

Kiromic BioPharma, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combi…

Full company profile